Premium
The inhibitory effect of tachyplesin I on thrombosis and its mechanisms
Author(s) -
Li Huimin,
Liu Bin,
Wu Jun,
Yu Huajun,
Huang Hui,
Chen Xi,
Chen Baoan,
Wu Shang,
Ma Jingyao,
Liu Wen,
Chen Xiaoyi,
Lan Liubo,
He Zhan,
Zhang Haitao
Publication year - 2019
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.13570
Subject(s) - thrombosis , pharmacology , platelet , thrombus , chemistry , in vivo , medicine , intraperitoneal injection , biology , microbiology and biotechnology
Thrombotic diseases are major cause of cardiovascular diseases. This study was designed to investigate the effect of tachyplesin I on platelet aggregation and thrombosis. Platelet aggregation was analysed with a whole blood aggregometer. The mice were employed to investigate the effect of tachyplesin I on thrombosis in vivo. Tachyplesin I inhibited thrombin‐induced platelet aggregation in a dose‐dependent manner. Furthermore, tachyplesin I significantly reduced thrombosis in carrageenan‐induced tail thrombosis model by intraperitoneal injection (0.1, 0.2 or 0.4 mg/kg) or intragastric administration (15, 30 or 60 mg/kg). Tachyplesin I also prolonged the bleeding time (BT) and clotting time (CT). The results revealed that tachyplesin I inhibited platelet aggregation and thrombosis by interfering the PI3K/AKT pathway. Tachyplesin I did not show significantly toxicity to mice under 300 mg/kg via intravenous injection. The results show that tachyplesin I inhibits thrombosis and has low toxicity. It is suggested that tachyplesin I has the potential to develop a new anti‐thrombotic drug.